High Demand on Accelerating and Optimizing Clinical R&D strategy in China
China's new drug approval policy has led to a recent spike in the volume of clinical trials. The quality of clinical research has become increasingly important, with several players simultaneously vying for sites and patients.
At HLT, we customize patient-centered digital patient screening strategies for research institutes and life science companies.
We optimize trial designing through feasibility analysis.
We accelerate the speed of patient recruitment and improve the accuracy of patient screening using AI technology.
We develop personalized solutions to ensure the successful conversion of potential patients.
We optimize patient screening strategies to improve efficiency.
What we do
HLT digital solutions can be fully leveraged in parallel with the entire R&D pathway in terms of RWE applications.
Spectrum of RWD/RWE
津公网安备 12011502000526号